Roche: thumbs up for lymphoma drug in US

(CercleFinance.com) - Roche announced on Friday that an advisory committee of the US FDA has recommended approval of its new treatment for diffuse large B-cell lymphoma.


The committee voted 11-2 in favour of marketing the combination, which combines two of its drugs, Polivy and Rituxan, with cyclophosphamide, doxorubicin and prednisone.

The FDA's decision is expected by 2 April. While the FDA is not bound to follow the advice of its expert committees, it generally relies on their opinions.

Diffuse large B-cell lymphoma is the most common form of non-Hodgkin's lymphoma, which is a cancerous disease of the lymphatic system.

It is caused by the uncontrolled multiplication of a subset of white blood cells called B cells.

No big deal though - at least market-wise, with Roche shares failing to rise on the Zurich stock exchange on Friday morning despite this announcement.



Copyright (c) 2023 CercleFinance.com. All rights reserved.